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Abstract 
Modern breast cancer treatment offers many women greater prospects of cure or 
lengthier, good quality survival than was possible in the past. Advances include:- 
improved diagnostic and staging procedures, sophisticated onco-plastic surgery, 
enhanced radiotherapy techniques and targeted systemic therapies. Much more 
attention has also been paid to cancer care delivery and access to specialist nurses, 
counsellors, support groups and services provided by breast cancer charities. 
However there are some concerns that these considerable improvements in 
treatment delivery and clinical outcomes have not led to similar benefits in the 
psychosocial, functional and sexual well-being of women. The impact that non-life 
threatening, long-term iatrogenic harms of otherwise efficacious anti-cancer 
treatments has on patients is often over-looked; this is in part due to the emphasis 
given to physician reported safety data in trials and the general exclusion of patient 
reported outcomes(PROs). A failure to utilise reliable PRO measures has meant that 
some problems are under-reported which consequently has hampered much needed 
research into ameliorative interventions. Systematic monitoring of quality of life-
threatening side-effects would permit early implementation of effective interventions 
and enhance long-term survivorship. Some examples of the pervasive difficulties that 
continue to affect survivors and evidence that certain interventions might help, are 
provided in this commentary. 
 
Introduction 
The past 3 decades have seen some extraordinary advances made in breast cancer 
treatment that offer women greater prospects of cure or lengthier, good quality 
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survival. Wide publicity is given quite rightly to better diagnostics, improved and less 
radical surgical techniques, increasing recognition of the need to manage the axilla, 
specialist oncoplastic surgeons producing more acceptable cosmetic outcomes, less 
damaging radiotherapy techniques and new procedures such as intraoperative 
radiotherapy that reduce treatment time and hospital visits. The explosion in 
knowledge regarding the genomics and molecular biology of breast cancer has also 
increased the number of chemotherapeutic options; trials report regularly the 
Progression Free Survival (PFS) and Overall Survival (OS) benefits of the newer 
systemic cytotoxic, hormone, and targeted therapies.  
Unfortunately, nothing comes without cost and despite these laudable therapeutic 
breakthroughs, considerable psychosocial and iatrogenic harms continue to be 
created by the diagnosis of breast cancer and its treatment. Most of the treatment 
related side-effects are acute, but some can be long-term impacting quality of life, 
and many women remain plagued by a plethora of physical, functional, emotional, 
financial and social challenges. Although responses vary at different stages of the 
disease trajectory, the impact of these issues preoccupies some women constantly. 
Importantly as few patients inhabit complete social vacuums, many of their concerns 
related to diagnosis and treatment, also affect others family members and friends. 
One positive outcome of psychosocial research exploring these areas of concern 
and the advocacy demands by women themselves, has been the increased 
awareness of the need to provide access to specialist nurses, patient navigators, 
counsellors and support groups. In tandem, some influential bodies, such as the 
Institute of Medicine (IOM), also made recommendations to promote evidence-
based, comprehensive, compassionate and coordinated survivorship care plans for 
all people diagnosed with cancer (1). 
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Despite all the new treatment options with their resultant improved clinical outcomes, 
it is questionable whether or not these endeavours have led to many comparable, 
measurable benefits in patients’ psychosocial, functional, occupational and sexual 
well-being. In this commentary we will outline some of the primary concerns that 
women with breast cancer continue to experience from diagnosis through 
survivorship, and then review some of the evidenced-based interventions that have 
made a difference.  
Psychological morbidity 
Much psychosocial research over the past 30 years has focused on the prevalence 
of psychological morbidity and has produced mixed results; some reports suggest 
that the prevalence of mood disorders such as anxiety and depression is high at 
diagnosis and is unremitting (2) whilst others have found a decline over time and 
little difference from that seen in age-matched controls without breast cancer. An 
interesting recent meta-analysis of 43 studies compared the prevalence of mood 
disorders in cancer survivors with their spouses (17 studies) and with healthy 
controls (26 studies). In a pooled analysis the prevalence of depression of 51,381 
cancer survivors was 11.6% compared with 10.2% in 217,630 healthy controls. The 
prevalence of anxiety was higher - 17.9% in 46,964 cancer survivors compared to 
13.9% in 226,467 healthy controls. Of note neither the prevalence of depression nor 
anxiety differed significantly between survivors and their spouses demonstrating the 
likely wider family support needs (3).  
Unfortunately much of the early research in this area has been hampered by 
inappropriate measures and methodology (4) and some extremely loose use of 
nomenclature; general distress is often confused with clinical anxiety states and 
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depressive or adjustment disorders. This might be due in part to the fact that most 
criteria for diagnosing anxiety and adjustment disorders were developed for 
psychiatrically ill not physically ill individuals. Many women with breast cancer do 
genuinely confront continual and real threats that their cancer will recur; 
consequently their ‘anxiety’ could be viewed as neither irrational nor inappropriate. 
One study of 3,300 long-term survivors (2 years post diagnosis) showed that 47% 
had a fear of recurrence (5).  
Being clear about the precise clinical characteristics of any psychological morbidity is 
important when determining the most appropriate prevention or screening strategies 
for those most at risk and ameliorative interventions.  The Amercian Society of 
Clinical Oncology (ASCO) has recently published assessment guidelines (6). A large 
number of management options is available. Women with clinical depression or 
anxiety need to be assessed properly and offered appropriate anti-depressant and 
anxiolytic therapy. For other forms of more generalized distress, a variety of 
interventions are available that range from cognitive behavior therapy, aromatherapy 
and massage, visualization, expressive therapeutic writing, art and music therapy. 
Some publications of well-conducted randomized controlled trials (RCTs) have 
shown that interventions incorporating elements of mindfulness-based stress 
reduction can improve mood state and reduce endocrine related side-effects (7) and 
that yoga can improve quality of life, fatigue, and measures of stress cortisol levels 
(8). 
Iatrogenic harms and side-effects of anti-cancer treatments 
Determining healthy long-term adjustment involves more than assessment of 
psychological morbidity; the deleterious impact exerted by many non-life threatening, 
6 
 
but quality of life threatening iatrogenic harms of otherwise efficacious anti-cancer 
treatments is often over-looked. Five commonly reported problems--lymphedema, 
fatigue, vasomotor complaints, sexual dysfunction and cognitive impairment--are 
considered below. 
Lymphedema 
Although there have been substantial improvements made within breast cancer 
surgery, with oncoplastic specialists able to offer procedures that are less radical and 
improve cosmesis, management of the axilla remains problematic. Some women feel 
that the aftermath of axillary surgery is worse than the surgery to the breast, creating 
substantial arm morbidity with lymphedema, pain, loss of sensation and mobility. 
Lymphedema in particular remains a problem for many women who have to undergo 
axillary treatment. A systematic review of 72 studies showed that the overall risk of 
lymphedema is 17% (9). Those factors influencing risk included more extensive 
surgery, the number of lymph nodes removed and obesity. There are at least 18 
RCTs comparing axillary lymph node dissection with sentinel node biopsy that show 
the risk of lymphedema to be 19.9% and 5.6% respectively. Sentinel node biopsy 
has been shown to reduce the amount of axillary surgery required without 
necessarily compromising survival. It also improves quality of life and reduces arm 
morbidity generally (10). As systemic therapy has improved outcomes for patients 
substantially, some doubt whether or not all women with early breast cancer and 
minimal nodal involvement really need to have axillary surgery at all, so large trials 
are required to demonstrate the safety of this approach. We do know that efforts to 
reduce arm morbidity and, importantly, to prevent lymphedema through optimal 
surgery is absolutely vital as few interventions help after its occurrence. The trials 
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comparing compression therapy with complex decongestive therapy (massage, 
exercise and skin care) are sadly equivocal (11). 
Fatigue  
Fatigue has probably replaced nausea and vomiting as the biggest post-treatment 
problem; it is usually acute but around 30% of women experience enervating fatigue 
that may continue for many years. The etiology of fatigue is complex; there is 
certainly a psychological component as it contributes to and/or is associated with 
reduced motivation, depression, concentration, impaired activities of daily living and 
poor overall heath related quality of life (12). However pro-inflammatory cytokines 
have been cited as the most likely underlying biological mechanism (13). 
Interventions are very important to initiate early. Although seemingly counter-
intuitive, rest is clearly the wrong option and exercise has been shown in many 
studies to improve not only fatigue but mood state also. An updated Cochrane 
review of 56 studies, 28 of which were in breast cancer, showed the benefits 
particularly of aerobic exercise, but not of resistance training (14).  Some patients 
find it quite difficult to engage with exercise programs post-treatment especially if 
they have not done this regularly prior to breast cancer; so they need considerable 
encouragement from care-givers, family, and friends or help from a motivational 
counsellor (15). The more reluctant might be helped by yoga, acupuncture and other 
mindfulness-based programs although the evidence base for these approaches is 
less compelling. ASCO have recently published guidelines for the screening, 
assessment and management of fatigue in adult survivors of cancer generally (16), 
which could be of benefit to women with breast cancer if implemented as part of their 
comprehensive cancer care. 
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Hormone therapy  
There are now many data demonstrating the benefits in ER+ women of extending 
adjuvant therapy to 5 or even 10 years (17). However, it is unfortunate that many of 
the women being treated with these drugs will derive no benefit whatever and only 
experience the iatrogenic harms. Side effects such as vasomotor complaints, vaginal 
dryness, loss of libido, and arthralgia are more than just a minor inconvenience and 
can lead to treatment discontinuation and suboptimal adherence (18). Patient self-
reports compared with physician reports show that many endocrine related side-
effects go under-recognized, under-reported, and under-treated (19, 20).  
Vasomotor complaints 
Vasomotor complaints include hot flushes, cold sweats and night sweats that lead to 
sleep difficulties which themselves may contribute to fatigue and poor concentration. 
Estimates vary according to the method of assessment employed and if problems 
are physician or patient reported, but approximately a third of women experience 
severe vasomotor side-effects attributable to selective estrogen receptor modulators 
or aromatase inhibitors (AIs) (21).  Although not life-threatening, these unpleasant 
consequences of treatment have a profound deleterious impact on overall sense of 
well-being and can affect adherence to oral therapies. Women do need effective 
non-hormonal treatments to ameliorate vaso-motor side-effects. A Cochrane review 
(22) looked at interventions that might help. The authors identified 10 
pharmacological RCTs that included clonidine, gabapentin, serotonin plus or minus 
norepinephrine reuptake inhibitors such as venlafaxine, paroxetine, sertraline and 
fluoxetine. All showed some activity in reducing frequency and severity of hot flushes 
but there are some contraindications limiting their use in all women. Six non-
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pharmacological studies were reviewed; these included some reasonable 
interventions such as relaxation therapy and acupuncture, together with other more 
dubious ones such as homeopathy and magnetic devices. Unfortunately, all 6 
studies had many methodological limitations; only relaxation therapy reduced both 
the frequency and the severity of hot flushes. More recent research has shown the 
benefits of behavioral approaches such as cognitive behavior therapy (CBT). A 
carefully conducted RCT of usual care or usual care plus group CBT (90 minute 
weekly sessions for 6 weeks) in women with problematic hot flushes and night 
sweats showed statistically significant reductions in problems 9 weeks after 
randomization, which were maintained at 26 weeks (23). The authors point out that 
as this safe type of behavioral intervention also has the additional benefits of 
improving mood state, sleep and overall quality of life, it seems useful to incorporate 
into breast cancer survivorship programs and could be implemented by appropriately 
trained nurses. 
Sexual problems 
There are many reports of the sexual difficulties created by breast cancer and its 
treatment. Vaginal dryness, discharge and dyspareunia combined with a loss of 
libido exert a negative impact upon patients and their partners. A study of >1000 
Australian women showed that 70% of breast cancer survivors experience sexual 
problems in the 2 years following diagnosis (24). Interestingly >80% of these patients 
claimed to have had a satisfying sex life prior to diagnosis. Those taking AIs were 
50% more likely to report problems than those taking tamoxifen or not having any 
endocrine therapy. 77% of the sample had hot flushes and night sweats, which were 
linked to reporting of sexual difficulties. Interventions to help loss of libido, vaginal 
dryness and dyspareunia are likely to be multi-factorial. Studies suggest that 
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moisturizers are probably better than lubricants for vaginal dryness, and 
combinations of moisturizers with pelvic floor exercises and relaxation training have 
been shown to be useful. (25).  
A more general point worth raising regarding the side-effects of otherwise effective 
treatments for breast cancer, concerns the reliance on clinician reported safety data 
rather than information collected via patient reported outcome measures in clinical 
trials. This has led to poor recognition of many of the difficulties some women 
experience, which in turn has hampered research into much needed ameliorative 
interventions.  
Cognitive Problems 
Many women treated with chemotherapy experience memory and attention 
difficulties, often described as “chemo-brain” or “chemo-fog”.  Wide variance exists in 
the proportions of women reporting problems, partly explained by differences in the 
neuropsychological tests employed in studies, and the sundry reference data and 
performance cut offs used when classifying test results (26). Although chemotherapy 
may be a key contributor to reported dysfunction, it is not the sole cause of “chemo 
brain” as a third of women perform poorly on cognitive tasks following surgery but 
prior to starting adjuvant therapies (27). In addition, some studies suggest endocrine 
therapies play a role (28), although a double blind RCT of anastrozole vs placebo 
(IBIS II) in postmenopausal women with a high risk of breast cancer found no 
differences between the groups for either self-reported problems or for any objective 
cognitive assessment (29). A recent prospective study of 189 women who had 
completed primary breast cancer treatments but had not started endocrine therapy 
found associations between subjective cognitive complaints and performance on 
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some neuropsychological tests, particularly for those who had received both 
chemotherapy and radiotherapy (30). 
The profile emerging from the plethora of studies is one of a mild cognitive 
impairment affecting learning and memory, processing speed and executive function 
(31). The mechanisms underlying the phenomenon are not clear but suggestions 
include stress and coping styles (32), direct neurotoxic injury, telomere shortening, 
oxidative stress, cytokine dysregulation, estrogen-mediated effects, and genetic 
polymorphisms (33). Pro-inflammatory cytokines can be used as markers for 
cognitive function in neurological disease, and recent literature suggests that 
elevated levels of peripheral pro-inflammatory cytokines may be related to cognitive 
problems in cancer patients (34). Additionally, decreased estrogen levels may serve 
as a link between multiple mechanisms potentiating the effects, particularly in those 
women who experience an acute menopause following treatment.   
Imaging studies have documented structural changes to the brain after completion of 
chemotherapy (35); again, however, some structural differences may have already 
been present before starting chemotherapy (36).   
The literature to date shows that in order to get a true understanding of the extent of 
this phenomenon, a multi-faceted approach is required. Well-designed prospective 
studies are needed. These would ideally assess women prior to breast surgery, use 
matched control groups, incorporate imaging and biological measures and records of 
all the additional “side effects” of treatments that could contribute to poor cognitive 
functioning, for example, anxiety, pain, fatigue and sleep disturbance. Having a good 
pre-illness measure of how someone is functioning, the work they do, their family 
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commitments and ability to cope with changes in their life is also important in order to 
measure the real life impact on the patient. 
Communication 
Communication affects adjustment to the diagnosis and patient decision-making 
about treatment. The increasing complexity of our understanding about breast 
cancer and the number of therapeutic options now available has made discussions 
between patients and doctors very much more difficult. Breast cancer is no longer a 
simple disease to explain and patients already experiencing emotional turmoil enter 
a strange new world of esoteric language and concepts. Helping patients navigate 
their way through all this to ensure that they can genuinely provide educated and 
informed consent to treatment plans demands excellent communication skills from 
the healthcare professionals involved with breast cancer care. There are also some 
good web-based information sources available on YouTube, together with DVDs, 
leaflets and booklets describing treatment options, outcomes with and without 
treatment, uncertainties and clinical trial enrollment. A Cochrane review of 55 trials of 
23 different screening/treatment decision support tools revealed that women who 
accessed them showed increased knowledge, more accurate risk perceptions, 
greater comfort with their decisions, and engaged in greater participation in decision-
making (37).  
An issue worthy of more research concerns the gross disparities that exist in survival 
outcomes among patients in groups with different socio-economic status (SES). Not 
only do those in lower SES groups have less time with healthcare professionals, but 
they are also not confident when asking for explanations about care plans and are 
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unlikely to access on-line informational sources or support services shown to help 
others in higher SES groupings. 
Metastatic Breast Cancer 
There has been far less psychosocial research in MBC compared to that in early 
disease. Women worldwide with advanced breast cancer attest to the sense of 
abandonment and neglect that they frequently feel (38). In a US study of expressive 
therapeutic writing in 176 women with MBC (39) 48% reported difficulty talking to 
others, often denying the severity of their illness or prognosis to close friends and 
relatives. Most had experienced shock, isolation, and a loss of control. As far as the 
need for further treatment was concerned, hair loss caused many ‘devastation’. Most 
activities of daily living changed substantially. Their primary physical problems of 
fatigue and pain led to them cancel activities, which caused guilt. For some, the 
inability to work was a major challenge, and frequent medical appointments 
produced emotional strain. Almost all found the impact on their families distressing. 
Clearly much more work needs to be done to help women unfortunate enough to 
develop metastatic disease. 
Conclusions 
It is debatable as to whether or not the provision of psychosocial care has kept pace 
with advances in breast cancer treatment. There is however a growing consensus 
that psychosocial care should be well-integrated into routine cancer care with an 
emphasis on changing from how long to how well patients live (40). There are good 
suggestions as to how this might be achieved in the developed world where 
resources are more likely to be available, but even in these communities, ensuring 
access for different ethnic and minority groups needs more effort (40). Although 
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worldwide, the provision and receipt of psychosocial care remains patchy, three 
developments in the past decade do enhance the likelihood that it will eventually 
become a component of comprehensive cancer care: 1) we are much better able to 
define standards; 2) many organizations have developed and are updating useful 
clinical practice guidelines; and 3) there has also been some excellent work in the 
development and implementation of measurable quality indicators. 
So are we getting better at enhancing survivorship in breast cancer? The answer is 
probably yes, but improvements have been mainly seen in early breast cancer not 
metastatic breast cancer, which needs addressing. Obviously, it remains important 
that there is global access to the best treatments and that thought is also given to the 
preferred routes of administration. We need to have systematic monitoring of side-
effects of treatment to permit early implementation of evidence-based interventions 
that might include more integrative oncology utilizing, where appropriate, non-
pharmacological modalities. There is still work to be done ensuring that all 
healthcare professionals have the communication skills required so they are capable 
of providing women with good, consistent, timely, accurate and understandable 
information.  
Women’s reactions to breast cancer and its treatment vary enormously irrespective 
of culture or class divides. For some, the diagnosis is a catastrophe, irreparably 
threatening their physical, functional, social, psychological, sexual and occupational 
well-being. For others it represents yet one more of life’s hurdles to overcome 
together with other social, educational and financial iniquities they face.  
Consequently, just as with the exciting advent of personalized and targeted 
medicine, we need similar endeavours producing more individualized psychosocial 
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care; communication should be flexible, adapted to the varying needs of individuals; 
appropriate screening should enable resources--counseling, relaxation therapy, 
yoga, exercise or mindfulness training--to be focused on those at most risk of the 
unremitting psychosocial dysfunction that compromises healthy survivorship. 
Spreading scarce supportive services thinly for all irrespective of their need or risk of 
poor adjustment, makes as much sense as administering hormone treatment or 
trastuzumab without information about receptor status. 
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